Salivary Gland Cancer Clinical Trials

7 recruiting

Salivary Gland Cancer Trials at a Glance

12 actively recruiting trials for salivary gland cancer are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running salivary gland cancer studies include M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, and Brigham and Women's Hospital.

Browse salivary gland cancer trials by phase

Treatments under study

About Salivary Gland Cancer Clinical Trials

Looking for clinical trials for Salivary Gland Cancer? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Salivary Gland Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Salivary Gland Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 2

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Salivary Gland CancerHER2 Gene Mutation
Dana-Farber Cancer Institute37 enrolled13 locationsNCT04620187
Recruiting
Phase 2

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Metastatic Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8Stage IV Major Salivary Gland Cancer AJCC v8+2 more
NRG Oncology146 enrolled150 locationsNCT05408845
Recruiting

The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers

Head and Neck CancerSalivary Gland CancerNasopharynx Cancer+2 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano13,600 enrolled10 locationsNCT05483374
Recruiting
Phase 2

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Salivary Gland CancersGland
M.D. Anderson Cancer Center30 enrolled1 locationNCT05884320
Recruiting
Early Phase 1

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Head and Neck CancerSquamous Cell Carcinoma of Head and NeckSalivary Gland Cancer+1 more
Brigham and Women's Hospital30 enrolled2 locationsNCT05553782
Recruiting

Integrated Cancer Repository for Cancer Research

Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled45 locationsNCT02012699
Recruiting
Not Applicable

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Stage I Colorectal Cancer AJCC v6 and v7Stage II Colorectal Cancer AJCC v7Stage III Colorectal Cancer AJCC v7+45 more
M.D. Anderson Cancer Center590 enrolled1 locationNCT01365169
Recruiting

PDO Based Drug Sensitive Test in R/M SGC

Salivary Gland CancersPatient Derived OrganoidDrug Sensitive Test in Vitro
Huashan Hospital40 enrolled2 locationsNCT06686979
Recruiting
Phase 2

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Salivary Gland CancerAdvanced Salivary Gland CarcinomaAdenoid Cystic Carcinoma+1 more
Glenn J. Hanna35 enrolled2 locationsNCT06805617
Recruiting
Phase 2

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Thyroid CancerSalivary Gland Cancer
National University Hospital, Singapore32 enrolled1 locationNCT06923826